Larvol Delta - Alzamend-Neuro-Receives-FDA-Study-May-Proceed-Letter-for-Phase-IIIA-Trial-Under-Its-Investigational-New-Drug-Application-for-an-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimers-Type

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20221031005314/en/Alzamend-Neuro-Receives-FDA-%E2%80%9CStudy-May-Proceed%E2%80%9D-Letter-for-Phase-IIIA-Trial-Under-Its-Investigational-New-Drug-Application-for-an-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimer%E2%80%99s-Type

Oct 31, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next